Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C4 Therapeutics's ROE % for the quarter that ended in Jun. 2026 was -39.27%. C4 Therapeutics's PB Ratio for the quarter that ended in Jun. 2026 was 2.32.
C4 Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was -16.93%.
C4 Therapeutics ROE % Adjusted to Book Value Related Terms
C4 Therapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for C4 Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C4 Therapeutics ROE % Adjusted to Book Value Chart
CCCC vs CMPX, AVIR, STRO: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, C4 Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C4 Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, C4 Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where C4 Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -16.93% mean?
C4 Therapeutics (CCCC) has a ROE % Adjusted to Book Value of -16.93% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on C4 Therapeutics and its competitors.
Is C4 Therapeutics' ROE % Adjusted to Book Value too high?
C4 Therapeutics' current ROE % Adjusted to Book Value is -16.93%. Overall, C4 Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C4 Therapeutics' ROE % Adjusted to Book Value compare to CMPX and AVIR?
C4 Therapeutics' ROE % Adjusted to Book Value of -16.93% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on C4 Therapeutics and its competitors. C4 Therapeutics's current ROE % Adjusted to Book Value is -16.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C4 Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, C4 Therapeutics (CCCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.05, compared to a current price of $4.12 — trading 100.7% above its estimated fair value. The current ROE % Adjusted to Book Value is -16.93%. C4 Therapeutics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For C4 Therapeutics (CCCC), the current ROE % Adjusted to Book Value is -16.93% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C4 Therapeutics (CCCC) Overvalued in 2026?
Based on GuruFocus' analysis, C4 Therapeutics stock appears to be overvalued.
The current stock price of $4.12 is trading 100.7% above its estimated GF Value™ of $2.05.
GuruFocus considers C4 Therapeutics to be Significantly Overvalued.
Key valuation signals for CCCC:
ROE % Adjusted to Book Value: -16.93%
GF Value™: $2.05 vs. price of $4.12 (100.7% above fair value)
No single metric tells the full story. See the CCCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
49GF Score
Get the complete analysis for CCCC
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCCC has been successfully added to your 
